CAS Number184475-35-2
SynonymsIressa; N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-4-quinazolinamine; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide; MFCD04307832; Irressat; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine; N-(3-chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; N-(3-Chlor-4-fluorphenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]chinazolin-4-amin; N-(3-Chlor-4-fluorphenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)chinazolin-4-amin; N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine; N-(3-chloro-4-fluorophényl)-7-méthoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; ZD-1839; Gefitinib; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinaz
Molecular FormulaC22H24ClFN4O3
Molecular Weight446.90
Purity≥98 (HPLC)%
Density1.3±0.1 g/cm3
Boiling Point586.8±50.0 °C at 760 mmHg
Melting Point119-1200C
Appearancepowder
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 184475-35-2 |
| Catalog No. | 2A-9010701 |
| Chinese Name | 吉非替尼 |
| Synonyms | Iressa; N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-4-quinazolinamine; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide; MFCD04307832; Irressat; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine; N-(3-chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; N-(3-Chlor-4-fluorphenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]chinazolin-4-amin; N-(3-Chlor-4-fluorphenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)chinazolin-4-amin; N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine; N-(3-chloro-4-fluorophényl)-7-méthoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; ZD-1839; Gefitinib; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinaz |
| Molecular Formula | C22H24ClFN4O3 |
| Molecular Weight | 446.90 |
| Purity | ≥98 (HPLC) |
| Density | 1.3±0.1 g/cm3 |
| Boiling Point | 586.8±50.0 °C at 760 mmHg |
| Melting Point | 119-1200C |
| Appearance | powder |
| Water Solubility | Water solubility: insoluble; slightly soluble: tet |
| Storage Condition | Store at RT |
| Application | Gefitinib is a potent epidermal growth factor receptor (EGFR) inhibitor with IC50 values of 2-37 nM in NR6wtEGFR cells. |
| HTC | 29143900 |
| PubChem ID | 329825996 |
| MDL Number | MFCD04307832 |
| SMILES | COC(C=C(N=CN=C1NC2=CC(Cl)=C(F)C=C2)C1=C3)=C3OCCCN4CCOCC4 |
| InChI | 1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27) |
| InChI Key | XGALLCVXEZPNRQ-UHFFFAOYSA-N |
| NACRES Code | NA.77 |
| UNSPSC | 12352200 |
| MSDS | msds/10701_1_184475_35_2.pdf |
| Use of | Gefitinib (ZD1839) is a EGFR tyrosine kinase inhibitor, with IC50 of 2-37 nM in NR6wtEGFR cells. Properties Name gefitinib Synonym More Synonyms Gefitinib Biological Activity Description Gefitinib (ZD1839) is a EGFR tyrosine kinase inhibitor, with IC50 of 2-37 nM in NR6wtEGFR cells. Related Catalog Signaling Pathways >> Autophagy >> Autophagy Signaling Pathways >> JAK/STAT Signaling >> EGFR Signaling Pathways >> Protein Tyrosine Kinase/RTK >> EGFR Research Areas >> Cancer Cell Assay Cancer cells are seeded in 96-well plates and are treated with different doses of Gefitinib (0.01-20 μM), Metformin or both for 72 hours. Cell proliferation is measured with the MTT assay. The IC50 values are determined by interpolation from the dose-response curves. Results represent the median of 3 separate experiments each conducted in quadruplicate. The results of the combined treatment are analyzed according to the method of Chou and Talalay by using the CalcuSyn software program[3]. References [1]. Pedersen MW, et al. Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII. Br J Cancer. 2005 Oct 17;93(8):915-23. [2]. Moasser MM, et al. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res. 2001 Oct 1;61(19):7184-8. [3]. Morgillo F, et al. Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines. Clin Cancer Res. 2013 Jul 1;19(13):3508-19. [4]. Miyake K, et al. Epidermal growth factor receptor-tyrosine kinase inhibitor (gefitinib) augments pneumonitis, but attenuates lung fibrosis in response to radiation injury in rats. J Med Invest. 2012;59(1-2):174-85. [5]. Noh CK, et al. Simultaneous quantification of volitinib and gefitinib in rat plasma by HPLC-MS/MS for application to a pharmacokinetic study in rats. J Sep Sci. 2017 Jul 27. [6]. Dhar D, et al. Liver Cancer Initiation Requires p53 Inhibition by CD44-Enhanced Growth Factor Signaling. Cancer Cell. 2018 Jun 11;33(6):1061-1077.e6. Chemical & Physical Properties Exact Mass 446.152100 PSA 68.74000 Index of Refraction 1.621 InChIKey XGALLCVXEZPNRQ-UHFFFAOYSA-N Storage condition Store at RT Safety Information Signal Word Warning Hazard Statements H302-H315-H319-H335 Precautionary Statements P301 + P312 + P330-P305 + P351 + P338 Hazard Codes Xi RIDADR NONH for all modes of transport WGK Germany 3 RTECS HP1149700 HS Code 29143900 Precursor & DownStream Precursor 7 CAS#:199327-61-2 Gefitinib impurity 5 CAS#:367-21-5 3-Chloro-4-fluo... CAS#:7357-67-7 4-(3-Chloroprop... CAS#:184475-71-6 DownStream 2 CAS#:847949-49-9 O-Desmethyl gef... CAS#:199327-61-2 Gefitinib impurity 5 |
| Tax Rebate | 13.0% |
| Supervision | None. MFN tariff: 6.5%. Ordinary tariff: 20.0% |
| Transport Info | Product name: Summary 2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
| Related Products in API & Advanced Intermediates | ||
|---|---|---|
| Gabapentin hydrochloride | 60142-96-3 | 2A-0200168 |
| gamma-Lumicolchicine | 6901-14-0 | 2A-9010682 |
| Ganciclovir | 82410-32-0 | 2A-9010685 |
| Ganciclovir sodium | 107910-75-8 | 2A-9010686 |
| Gatifloxacin lactate | 160738-57-8 | 2A-9010698 |
| Gemcitabine | 95058-81-4 | 2A-9010704 |
| Gemcitabine hydrochloride | 122111-03-9 | 2A-9010705 |
| Gemifloxacin | 175463-14-6 | 2A-9010708 |
| Gentamicin B | 36889-15-3 | 2A-9010715 |
| Gestodene | 60282-87-3 | 2A-9010720 |
| Browse all API & Advanced Intermediates products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS